Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Nanogen

This article was originally published in The Gray Sheet

Executive Summary

Nanogen: Diagnostics developer plans an initial public offering of up to $40 mil. in common stock. A preliminary prospectus filed with the Securities and Exchange Commission does not specify the anticipated price per share or number of shares to be offered. San Diego-based Nanogen is developing a fully automated, microelectronics-based platform technology for rapid identification and analysis of test samples containing charged molecules, which incorporates a laser-based fluorescence scanner to detect molecular binding. The system has broad commercial applicability in the fields of medical diagnostics, biomedical research, genomics, genetic testing and drug discovery, Nanogen maintains. The firm has a May 1997 joint venture with Becton Dickinson for development of infectious disease diagnostics based on the technology. Separate collaborative agreements signed in December with Hoechst and Elan cover development of drug discovery tools and genomic research applications, respectively.

You may also be interested in...



ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel